In the present study, our subgroup analyses revealed that the influence of CBM588 on the efficacy of chemoimmunotherapy combinations varied depending on tumor PD-L1 expression in patients with NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.